

denosumab subcutaneous injection (XGEVA)

Diagnoses Considered for Coverage:

- Prevention of skeletal-related events in patients with bone metastases from solid tumors
- Giant cell tumor of bone
- Hypercalcemia of malignancy
- Prevention of skeletal-related events in multiple myeloma

Coverage Criteria:

For diagnosis of prevention of skeletal-related events in patients with bone metastases from solid tumors:

- Documentation of metastatic bone disease by scan or X-ray, **and**
- Dose does not exceed 120 mg given subcutaneously every 4 weeks.

For diagnosis of treatment of giant cell tumor of bone:

- Patient at least 18 years old or adolescent whose bones have matured, **and**
- Disease is unresectable, metastatic, recurrent, or resectable with unacceptable morbidity, **and**
- Dose does not exceed 120 mg given SQ on day #1, day #8 and day #15 of first month of therapy, followed by 120 mg SQ given every 4 weeks

For diagnosis of treatment of hypercalcemia of malignancy:

- Inadequate response to prior intravenous bisphosphonate therapy [zoledronic acid (Zometa) or pamidronate (Aredia)] within the last 30 days, **and**
- Dose does not exceed 120 mg given SQ on day #1, day #8 and day #15 of first month of therapy, followed by 120 mg SQ given every 4 weeks

For diagnosis of prevention of skeletal-related events in multiple myeloma:

- Patient has evidence of bone disease, **and**
- Dose does not exceed 120 mg given subcutaneously every 4 weeks.

Coverage Duration: one year

Effective: 01/31/2024